A recent study showed that KRAS G12C mutations occur between 3–14% of different cancer types including NSCLC, colorectal cancer, appendiceal, and small bowel cancer [21], suggesting also that, in NSCLC, female patients harbored significantly more KRAS G12C mutations than male patients [21]. This evidence concerns the gene KRAS and cancer.